# A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

> **NCT04566692** · PHASE4 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 33 (actual)

## Conditions studied

- Primary Immunodeficiency

## Interventions

- **BIOLOGICAL:** IGSC 20%

## Key facts

- **NCT ID:** NCT04566692
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-25
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566692, "A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04566692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*